A Phase 3 interventional study of Exparel and Bupivacaine Hydrochloride in Lower Extremity Surgery, Bunion and Metatarsophalangeal Fushion, sponsored by Pacira Pharmaceuticals, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-18.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Bunion with a site in United States — 1 open to participants now, 4 under way, 2 of them phase 3. Bunion · United States.
Among the 37 studies in Bunion with a site in United States, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2020, is one of 12 in phase 3, and was the 26th registered.
58 studies on the registry are indexed under Bunion; 5 are open to participants now.
Browse Bunion studies →1 of the 37 studies in Bunion with a site in United States is open now. Recruiting first, the newest first:
Cali Pharmaceuticals LLC · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1 Bunion study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 100 across 47 interventional studies indexed under Bunion.
Median enrollment 124 across the 34 interventional studies, 8 across the 3 observational. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Pacira BioSciences, Inc. has 5 studies filed under Bunion — fewer than ten, so there is no comparison to draw.
2 of the studies in Bunion with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07490496Phase 3Cali Pharmaceuticals LLCPhase 3 Bunionectomy Study | 2027-06-30 |
| NCT06486753The Methodist Hospital Research InstituteLSTR in Chevron Osteotomy | 2027-03-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Bunion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, double blinded, active controlled study in approximately 120 subjects undergoing lower extremity surgeries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL mixed with 20 mL saline
Drug: Exparel
subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL admixed with 20 mL (50 mg) 0.25% bupivacaine HCl.
Drug: Exparel · Drug: Bupivacaine Hydrochloride
subjects randomized to this treatment arm will receive 40 mL (100 mg)0.25% bupivacaine HCl.
Drug: Bupivacaine Hydrochloride
EXPAREL (bupivacaine liposome injectable suspension)
0.25% bupivacaine
Magnitude of the Analgesic Effect (NRS Pain Intensity) (AUC)
To compare the magnitude of the analgesic effect (NRS pain intensity scores) following a single dose injection of EXPAREL vs. bupivacaine hydrochloride (HCl) when administered as combined sciatic (in the popliteal fossa) and saphenous (in the adductor canal) nerve blocks in subjects undergoing lower extremity surgeries. Numerical Rating Scale: an 11 point scale 0=no pain, 10= the worst pain imaginable. The area under the curve (AUC) of the NRS pain intensity scores from 0 to 96 hours post-surgery comparing EXPAREL to 0.25% bupivacaine HCl
Time frame: Post surgery - 96 hours
Total Opioid Consumption
Total Opioid Consumption in oral morphine equivalents
Time frame: 0 hours to 96 hours
Time to First Opioid
Time to First Opioid following a single dose of EXPAREL vs. Bupivacain HCl
Time frame: Post Surgery through Day 14
| Milestone | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| Started | 40 | 41 | 40 |
| Completed | 39 | 40 | 39 |
| Not completed | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 | 0 |
To compare the magnitude of the analgesic effect (NRS pain intensity scores) following a single dose injection of EXPAREL vs. bupivacaine hydrochloride (HCl) when administered as combined sciatic (in the popliteal fossa) and saphenous (in the adductor canal) nerve blocks in subjects undergoing lower extremity surgeries. Numerical Rating Scale: an 11 point scale 0=no pain, 10= the worst pain imaginable. The area under the curve (AUC) of the NRS pain intensity scores from 0 to 96 hours post-surgery comparing EXPAREL to 0.25% bupivacaine HCl
| score on a scale*hours | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| Magnitude of the Analgesic Effect (NRS Pain Intensity) (AUC) | 298.65 ± 173.524 | 358.10 ± 223.610 | 380.05 ± 220.878 |
Total Opioid Consumption in oral morphine equivalents
| OMED mg | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| Total Opioid Consumption | 20.68 (13.51 to 31.65) | 23.56 (15.54 to 35.73) | 19.84 (12.72 to 30.96) |
Time to First Opioid following a single dose of EXPAREL vs. Bupivacain HCl
| hours | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| Time to First Opioid | 5.65 (0.72 to 13.55) | 11.93 (5.15 to 16.28) | 16.67 (7.53 to 22.33) |
Collected over Adverse events (AEs) and SAEs were recorded from the time of informed consent through POD 14.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL Arm | 0/39 (0%) | 0/39 (0%) | 28/39 (71.8%) |
| EXPAREL Admix Arm | 0/41 (0%) | 0/41 (0%) | 29/41 (70.7%) |
| Bupivacaine HCl Arm | 0/39 (0%) | 0/39 (0%) | 31/39 (79.5%) |
| Event | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| NauseaGastrointestinal disorders | 8/39 | 12/41 | 7/39 |
| ConstipationGastrointestinal disorders | 9/39 | 11/41 | 11/39 |
| ParaesthesiaNervous system disorders | 5/39 | 3/41 | 11/39 |
| HeadacheNervous system disorders | 10/39 | 4/41 | 7/39 |
| HypoaesthesiaNervous system disorders | 8/39 | 9/41 | 0/39 |
| VomitingGastrointestinal disorders | 1/39 | 6/41 | 2/39 |
| DizzinessNervous system disorders | 3/39 | 2/41 | 2/39 |
| PruritisSkin and subcutaneous tissue disorders | 3/39 | 1/41 | 1/39 |
| PyrexiaGeneral disorders | 2/39 | 0/41 | 1/39 |
| Blood Pressure IncreasedInvestigations | 2/39 | 2/41 | 1/39 |
| Age, Customized(Participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| <45 years | 11 | 14 | 18 | 43 |
| >/=45 years | 28 | 26 | 22 | 76 |
| Sex: Female, Male(Participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| Female | 35 | 36 | 27 | 98 |
| Male | 4 | 4 | 13 | 21 |
| Ethnicity (NIH/OMB)(Participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 12 | 15 | 37 |
| Not Hispanic or Latino | 28 | 26 | 25 | 79 |
| Unknown or Not Reported | 1 | 2 | 0 | 3 |
| Race (NIH/OMB)(Participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 1 | 0 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 11 | 7 | 23 |
| White | 32 | 26 | 30 | 88 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| American Society of Anesthesiologists (ASA) Classification(Participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| ASA 1 | 15 | 12 | 23 | 50 |
| ASA 2 | 24 | 26 | 17 | 67 |
| ASA 3 | 0 | 2 | 0 | 2 |
| ASA >/= 4 | 0 | 0 | 0 | 0 |
| Height(participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| <165 cm | 20 | 21 | 20 | 61 |
| >/= 165 cm | 19 | 19 | 20 | 58 |
| Weight(kg) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| Mean | 77.05 (43.5 to 120.2) | 83.03 (49.8 to 117.3) | 77.34 (52.9 to 136.6) | 79.16 (43.5 to 136.6) |
| Body Mass Index (BMI) kg/m2(participants) | EXPAREL Arm | EXPAREL Admix Arm | Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| <25 kg/m2 | 10 | 9 | 10 | 29 |
| 25- <30kg/m2 | 15 | 10 | 19 | 44 |
| >/= 30 kg/m2 | 14 | 21 | 11 | 46 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Apr 2021, 5 months.
Results were first posted in Jul 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Liposomal Bupivacaine · Bupivacaine